Literature DB >> 16025419

Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene.

J K Rybakowski1, A Suwalska, M Skibinska, A Szczepankiewicz, A Leszczynska-Rodziewicz, A Permoda, P M Czerski, J Hauser.   

Abstract

INTRODUCTION: Brain-derived neurotrophic factor (BDNF) has been involved in the pathogenesis of bipolar mood disorder and in the mechanism of mood-normalizing action of lithium. The aim of this study was to find a possible association between lithium prophylactic effect in bipolar patients and two polymorphisms of BDNF gene.
METHODS: Eighty-eight patients (35 males, 53 females) with bipolar illness were studied. Duration of lithium prophylaxis ranged between 5-27 years (mean 15 years). Three categories of prophylactic lithium response were delineated: excellent responders (ER), partial responders (PR) and non-responders (NR). All patients were genotyped for two polymorphisms of BDNF gene: Val66Met and -270C/T.
RESULTS: The Val/Met genotype of Val66Met polymorphism occurred more frequently (p = 0.037) and there was a trend for a higher incidence of Met allele (p = 0.076), in ER than in NR. A trend for C/T genotype and T allele of -270C/T polymorphism was observed to occur more frequently in ER than in NR (p = 0.057 and p = 0.065, respectively).
CONCLUSION: The data obtained suggest that polymorphism of BDNF gene may be connected with a quality of lithium prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16025419     DOI: 10.1055/s-2005-871239

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  22 in total

Review 1.  Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects.

Authors:  Jorge A Quiroz; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji
Journal:  Neuropsychobiology       Date:  2010-05-07       Impact factor: 2.328

Review 2.  BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.

Authors:  J J Rakofsky; K J Ressler; B W Dunlop
Journal:  Mol Psychiatry       Date:  2011-09-20       Impact factor: 15.992

Review 3.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

5.  Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.

Authors:  M S Breen; C H White; T Shekhtman; K Lin; D Looney; C H Woelk; J R Kelsoe
Journal:  Pharmacogenomics J       Date:  2016-07-12       Impact factor: 3.550

Review 6.  Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Bernhard T Baune
Journal:  EPMA J       Date:  2017-09-05       Impact factor: 6.543

7.  Predictors of lithium response in bipolar disorder.

Authors:  Sarah K Tighe; Pamela B Mahon; James B Potash
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

Review 8.  Lithium's role in neural plasticity and its implications for mood disorders.

Authors:  J D Gray; B S McEwen
Journal:  Acta Psychiatr Scand       Date:  2013-04-26       Impact factor: 6.392

9.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 10.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.